Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 2 | Cardio-Oncology

Fig. 2

From: Dexrazoxane prevents vascular toxicity in doxorubicin-treated mice

Fig. 2

Vascular reactivity in thoracic descending aorta. DEXRA combined with DOX does not affect endothelial-dependent vasorelaxation A Vascular reactivity, measured ex vivo. Vasodilatation was assessed endothelial-dependent and -independent with ACh and DEANO, respectively. B Vasocontraction and basal NO were measured with PE and PE + L-NAME. At week 6 a cumulative dose of 24 mg/kg DOX and 240 mg/kg DEXRA was used. Data shows mean ± SEM. ACh, acetylcholine; DEANO, diethylamine NONOate; L-NAME, Nω-nitro-L-arginine methyl ester; PE, phenylephrine. A & B: Two-way ANOVA, *, **, p < 0.05, p < 0.01

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us